Nitric oxide, the biological mediator of the decade: fact or fiction?

Nitric oxide (NO), an atmospheric gas and free radical, is also an important biological mediator in animals and humans. Its enzymatic synthesis by constitutive (c) and inducible (i) isoforms of NO synthase (NOS) and its reactions with other biological molecules such as reactive oxygen species are well characterized. NO modulates pulmonary and systemic vascular tone through its vasodilator property. It has antithrombotic functions and mediates some consequences of the innate and acute inflammatory responses; cytokines and bacterial toxins induce widespread expression of iNOS associated with microvascular and haemodynamic changes in sepsis. Within the lungs, a diminution of NO production is implicated in pathological states associated with pulmonary hypertension, such as acute respiratory distress syndrome: inhaled NO is a selective pulmonary vasodilator and can improve ventilation-perfusion mismatch. However, it may have deleterious effects through modulating hypoxic pulmonary vasoconstriction. Inhibitors of NOS may be of benefit in inotrope-refractory septic shock, but toxicity of newly developed selective iNOS inhibitors have prevented clinical trials of efficacy. An expanding literature on the origins and measurement of NO in exhaled breath implicates NO as a potentially useful marker of disease activity in respiratory tract inflammation in the future. This report reviews some aspects of research into the clinical importance of nitric oxide.

This article has been cited by other articles:

				C. Brindicci, K. Ito, P. J. Barnes, and S. A. Kharitonov Effect of an Inducible Nitric Oxide Synthase Inhibitor on Differential Flow-Exhaled Nitric Oxide in Asthmatic Patients and Healthy Volunteers Chest, August 1, 2007; 132(2): 581 - 588. [Abstract] [Full Text] [PDF]

				K. Nishijima, Y.-S. Ng, L. Zhong, J. Bradley, W. Schubert, N. Jo, J. Akita, S. J. Samuelsson, G. S. Robinson, A. P. Adamis, et al. Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury Am. J. Pathol., July 1, 2007; 171(1): 53 - 67. [Abstract] [Full Text] [PDF]

				B. S. Zuckerbraun, B. Y. Chin, B. Wegiel, T. R. Billiar, E. Czsimadia, J. Rao, L. Shimoda, E. Ifedigbo, S. Kanno, and L. E. Otterbein Carbon monoxide reverses established pulmonary hypertension J. Exp. Med., September 4, 2006; 203(9): 2109 - 2119. [Abstract] [Full Text] [PDF]

				E. B. Manukhina, H. F. Downey, and R. T. Mallet Role of nitric oxide in cardiovascular adaptation to intermittent hypoxia. Experimental Biology and Medicine, April 1, 2006; 231(4): 343 - 365. [Abstract] [Full Text] [PDF]

				R Ratnawati and P S Thomas Exhaled nitric oxide in paediatric asthma Chronic Respiratory Disease, July 1, 2005; 2(3): 163 - 174. [Abstract] [PDF]

				K. Sydow, C. E Mondon, and J. P Cooke Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA Vascular Medicine, July 1, 2005; 10(1_suppl): S35 - S43. [Abstract] [PDF]

				K. Sydow, C. E Mondon, and J. P Cooke Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA Vascular Medicine, May 1, 2005; 10(2_suppl): S35 - S43. [Abstract] [PDF]

				M. A. Vincent, E. J. Barrett, J. R. Lindner, M. G. Clark, and S. Rattigan Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E123 - E129. [Abstract] [Full Text] [PDF]

				E.D. Moloney and T.W. Evans Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome Eur. Respir. J., April 1, 2003; 21(4): 720 - 727. [Abstract] [Full Text] [PDF]

				O.V. Evgenov, N.V. Evgenov, T.E. Mollnes, and L.J. Bjertnaes Methylene blue reduces pulmonary oedema and cyclo-oxygenase products in endotoxaemic sheep Eur. Respir. J., October 1, 2002; 20(4): 957 - 964. [Abstract] [Full Text] [PDF]

				S. A. A. Comhair and S. C. Erzurum Antioxidant responses to oxidant-mediated lung diseases Am J Physiol Lung Cell Mol Physiol, August 1, 2002; 283(2): L246 - L255. [Abstract] [Full Text] [PDF]

				C. L BAILEY, R. N CHANNICK, and L. J RUBIN A new era in the treatment of primary pulmonary hypertension Heart, March 1, 2001; 85(3): 251 - 252. [Full Text]

				S. J. Wort, J. A. Mitchell, and T. W. Evans Inducible nitric oxide synthase: a tissue-specific affair? Am J Physiol Lung Cell Mol Physiol, March 1, 2001; 280(3): L387 - L389. [Full Text] [PDF]

				R. Neviere, B. Guery, S. Mordon, F. Zerimech, S. Charre, F. Wattel, and C. Chopin Inhaled NO reduces leukocyte-endothelial cell interactions and myocardial dysfunction in endotoxemic rats Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H1783 - H1790. [Abstract] [Full Text] [PDF]

				E. GABBAY, E. HAYDN WALTERS, B. ORSIDA, H. WHITFORD, C. WARD, T. C. KOTSIMBOS, G. I. SNELL, and T. J. WILLIAMS In Stable Lung Transplant Recipients, Exhaled Nitric Oxide Levels Positively Correlate with Airway Neutrophilia and Bronchial Epithelial iNOS Am. J. Respir. Crit. Care Med., December 1, 1999; 160(6): 2093 - 2099. [Abstract] [Full Text]

				S. SINGH, S J. WORT, and T. W EVANS Inducible nitric oxide and pulmonary infection Thorax, November 1, 1999; 54(11): 959 - 960. [Full Text]

				N. K. Veeramachaneni, A. H. Harken, and C. B. Cairns Clinical Implications of Hemoglobin as a Nitric Oxide Carrier Arch Surg, April 1, 1999; 134(4): 434 - 437. [Abstract] [Full Text] [PDF]

				A. S. SLUTSKY and L. N. TREMBLAY Multiple System Organ Failure . Is Mechanical Ventilation a Contributing Factor? Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1721 - 1725. [Full Text] [PDF]

				A J Fisher, E Gabbay, T Small, S Doig, J H Dark, and P A Corris Cross sectional study of exhaled nitric oxide levels following lung transplantation Thorax, June 1, 1998; 53(6): 454 - 458. [Abstract] [Full Text]